ATE259378T1 - Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen - Google Patents

Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen

Info

Publication number
ATE259378T1
ATE259378T1 AT96939218T AT96939218T ATE259378T1 AT E259378 T1 ATE259378 T1 AT E259378T1 AT 96939218 T AT96939218 T AT 96939218T AT 96939218 T AT96939218 T AT 96939218T AT E259378 T1 ATE259378 T1 AT E259378T1
Authority
AT
Austria
Prior art keywords
brca2
cancer
sequencing
identification
susceptileity
Prior art date
Application number
AT96939218T
Other languages
English (en)
Inventor
Phillip Andrew Futreal
Richard Francis Wooster
Alan Ashworth
Michael Rudolf Stratton
Original Assignee
Cancer Res Campaign Tech
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE259378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9523959.6A external-priority patent/GB9523959D0/en
Priority claimed from GBGB9525555.0A external-priority patent/GB9525555D0/en
Priority claimed from GBGB9617961.9A external-priority patent/GB9617961D0/en
Application filed by Cancer Res Campaign Tech, Univ Duke filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of ATE259378T1 publication Critical patent/ATE259378T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT96939218T 1995-11-23 1996-11-25 Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen ATE259378T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9523959.6A GB9523959D0 (en) 1995-11-23 1995-11-23 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9525555.0A GB9525555D0 (en) 1995-12-14 1995-12-14 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9617961.9A GB9617961D0 (en) 1996-08-28 1996-08-28 Materials and methods relating to the diagnosis and prophylactic and therapeuti treatment of cancer
PCT/GB1996/002904 WO1997019110A1 (en) 1995-11-23 1996-11-25 Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof

Publications (1)

Publication Number Publication Date
ATE259378T1 true ATE259378T1 (de) 2004-02-15

Family

ID=27267991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939218T ATE259378T1 (de) 1995-11-23 1996-11-25 Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen

Country Status (10)

Country Link
US (1) US6045997A (de)
EP (1) EP0858467B1 (de)
JP (1) JP2001507563A (de)
AT (1) ATE259378T1 (de)
AU (1) AU707636C (de)
CA (1) CA2238010A1 (de)
DE (1) DE69631540T2 (de)
DK (1) DK0858467T3 (de)
ES (1) ES2217328T3 (de)
WO (1) WO1997019110A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2239733C (en) * 1995-12-18 2001-04-03 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
AU773601B2 (en) * 1995-12-18 2004-05-27 Endorecherche Inc. Chromosome 13-linked breast cancer susceptibility gene
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
DE69830395T2 (de) * 1997-03-20 2006-01-26 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Iterative resequenzierung
US20140302494A9 (en) * 1997-08-15 2014-10-09 Myriad Genetics, Incorporated Method of analyzing a brca2 gene in a human subject
WO1999009164A1 (en) * 1997-08-15 1999-02-25 Oncormed, Inc. Coding sequence haplotypes of the human brca2 gene
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US6562958B1 (en) * 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
DE60025704T2 (de) * 1999-02-24 2006-09-07 Juan Saus Das goodpasture-antigen bindende protein
EP1287162A2 (de) 1999-10-21 2003-03-05 Case Western Reserve University Ermittlung des genexpressionsprofils bei entzündlichen darmerkrankungen
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
EP1953243B1 (de) 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Polynukleotide im Zusammenhang mit Darmkrebs
WO2002004628A2 (en) 2000-07-06 2002-01-17 Genvec, Inc. Method of identifying a binding partner of a gene product
DE50015173D1 (de) 2000-07-13 2008-07-03 Ct Concept Technologie Ag Verfahren und vorrichtung zur zustandsabhängigen regelung des transienten verhaltens von leistungshalbleiterschaltern
US20030175749A1 (en) * 2001-12-08 2003-09-18 Jong-Yoon Chun Annealing control primer and its uses
WO2003104429A2 (en) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7892823B2 (en) * 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8759089B2 (en) * 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US20130058979A1 (en) * 2009-11-30 2013-03-07 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
ES2896404T3 (es) 2014-04-04 2022-02-24 Crown Bioscience Inc Taicang Métodos para determinar la capacidad de respuesta a inhibidores de MEK/ERK
US11773449B2 (en) 2017-09-01 2023-10-03 The Hospital For Sick Children Profiling and treatment of hypermutant cancer
CN116179710B (zh) * 2023-03-14 2023-11-24 成都诺森医学检验有限公司 基于高通量测序平台的brca1/2基因突变检测的引物组、文库构建与环化方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393502B1 (de) * 1989-04-19 1995-12-27 F. Hoffmann-La Roche Ag Auflösbare Interferon-gamma-Rezeptoren sowie Verfahren zu deren Herstellung
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP0739894A4 (de) * 1994-01-14 1997-03-26 Taisho Pharmaceutical Co Ltd Thiazolin-derivate
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer

Also Published As

Publication number Publication date
DE69631540T2 (de) 2005-01-27
EP0858467B1 (de) 2004-02-11
DK0858467T3 (da) 2004-06-14
AU7635096A (en) 1997-06-11
AU707636C (en) 2003-01-16
WO1997019110A1 (en) 1997-05-29
AU707636B2 (en) 1999-07-15
US6045997A (en) 2000-04-04
CA2238010A1 (en) 1997-05-29
DE69631540D1 (de) 2004-03-18
ES2217328T3 (es) 2004-11-01
EP0858467A1 (de) 1998-08-19
JP2001507563A (ja) 2001-06-12

Similar Documents

Publication Publication Date Title
ATE259378T1 (de) Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
ATE280226T1 (de) Genetische marker für brust und eierstockkrebs
DE69333815D1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
DE69707985D1 (de) Kodierende sequenzen des menschlichen brca1-gens
SI0917571T1 (en) Agouti-related gene
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO2002095051A3 (en) Mage-a3 peptides presented by hla class ii molecules
DE3650266D1 (de) DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von "mullerian inhibiting substance"-ähnlichen Polypeptiden.
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
EP1005539A4 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
EP1100815A4 (de) Von protease typ ii spaltbares peptid
DE602004028381D1 (en) Er of regulator of imprinted sites) moleküls
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
IL149416A0 (en) Human enzymes of the metalloprotease family
ATE329055T1 (de) Methode zur erstellung von genexpressionsprofilen
EP0960128A4 (de) In Krebszellen überexprimiertes Genprodukt
WO2005049818A3 (en) Genes encoding human deubiquitinating enzymes
WO2001060985A3 (en) Compositions, methods and kits relating to uridine phosphorylase gene mutations
DE60222669D1 (de) Asthma-assoziiertes gen
BR9907720A (pt) Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transpormada, polipeptìdeo de elf-4e, método de alteração do nìvel de expressão de uma proteìna elf-4e, em uma célula hospedeira, método de obtenção de um de um fragmento de ácido nucléico codificador de toda ou uma parte substancial da sequência aminoácida codificadora de uma proteìna elf-4e e produto

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0858467

Country of ref document: EP